Beroctocog alfa

Drug Profile

Beroctocog alfa

Alternative Names: GC 1101; GC 1101C; GreenGene F; r-FVIII - Green Cross; Recombinant factor VIII - Green Cross

Latest Information Update: 21 Apr 2015

Price : $50

At a glance

  • Originator Green Cross
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 23 Dec 2013 Green Cross Corporation initiates enrolment in a phase III extension trial for Haemophilia A (In adolescents, In adults) in United Kingdom and USA (EudraCT2013-004383-62)
  • 22 Aug 2013 Recombinant factor VIII - Green Cross is available for licensing as of 22 Aug 2013. http://www.greencross.com/eng/business/licensigout.do
  • 01 Apr 2013 Phase-III clinical trials in Haemophilia A (In adolescents, In adults) in Canada, New Zealand, Poland, Russia and Ukraine (IV) after January 2013 (NCT01619046)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top